NYSE
Evommune, Inc. (EVMN)
♥ 597 Thanks from members
Evommune, Inc. (EVMN) faces a mixed market reception following a key clinical setback for its MRGPRX2 inhibitor EVO756 in chronic spontaneous urticaria, leading to analyst downgrades and share price volatility, though cash runway extends through 2028 with ongoing trials in atopic dermatitis and migraine prophylaxis.